Developer docs
API playgroundTry for free, no card

Search company profiles

Smileyscope

Full company profile

uuid0002jll

Namestring
Smileyscope
Legal namestring
Smileyscope Holding Inc
Websiteurl
smileyscope.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Smileyscope is a Melbourne-founded, Austin-headquartered digital therapeutics company that has developed a medical-grade virtual reality platform to reduce procedural pain and anxiety in clinical settings. Its core technology combines proprietary antimicrobial, wipeable VR hardware (no controllers, touchscreen interface, offline operation without WiFi or Bluetooth) with clinical software built around a patented method called Procedural Choreography™, which reframes real-world sensations into supportive VR experiences synchronized to procedure timing. The platform spans three principal modes — Therapy Mode (FDA Class II cleared as a "Virtual Reality Analgesic"), Imaging Mode (MRI/CT simulation with graded exposure therapy reducing sedation needs by up to 92%), and a Mindfulness/Relaxation suite — and is supported by what the company describes as the largest randomized controlled trial in procedural VR (Chan et al, J Peds, 2019), demonstrating up to 60% pain reduction and 40% anxiety reduction. In 2025 the company extended the platform into women's health with the Lume product and into brain performance via the NeuroTrainer acquisition.

The company generates revenue through tiered multi-year subscription plans (Silver, Gold, Platinum) that bundle VR hardware, software licenses, training, warranties, and support on a 12-month minimum contract basis, with volume discounts for 5+ unit orders. Go-to-market is a hybrid enterprise field sales and inside sales motion targeting children's hospitals, NHS trusts, health systems, and specialty clinics across North America, Australia, the UK, and the Middle East, supplemented by clinical-evidence-led content marketing, conference presence, and reference-customer word of mouth. Customers include St. Jude, Harvard, King's College Hospital Dubai, Monash Children's, Nicklaus Children's, Perth Children's, Oxford University Hospital NHS, Chelsea and Westminster NHS, Rush Medical Center, and others, with adoption reaching 100% of Australian children's hospitals within 12 months of launch in 2022.

The company is operationally profitable in Australia and has raised approximately $10.7M in a 2025 funding round alongside a 2023 seed-prime round led by Breakthrough Victoria, Ten13, Alice Anderson Fund, and MedAngels. With 11-50 employees and FDA Class II, CE, TGA, and MHRA clearances across its primary markets, Smileyscope occupies a regulatory-first position in VR-based procedural analgesia with a defensible clinical evidence base and an expanding footprint across pediatric, women's health, imaging, and brain-performance applications.

Short descriptiontext

Smileyscope is a medical-grade virtual reality digital therapeutics company that reduces procedural pain and anxiety in pediatric, women's health, and imaging settings. Its FDA Class II-cleared VR platform is deployed across hospitals in North America, Australia, the UK, and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
virtual reality therapy, pediatric pain management, digital therapeutics, procedural anxiety relief, medical VR hardware
Industry3 codes
PRIMARYHLACANAL
Pediatrics & Adolescent Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAFAJAC
Healthcare & Clinical Simulation (Surgery, Nursing, EMT, Patient Interaction)
Education/Education Technology (EdTech) & Digital Learning/AR/VR/XR, Simulations & Immersive Learning
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Services-Health Services8000
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Digital Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1VR Hardware and Software Subscriptions
TypeSubscription Recurring
Description

The company generates revenue primarily through tiered subscription plans (Silver, Gold, Platinum) that bundle medical-grade VR hardware with software licenses, training, warranties, and ongoing support. Plans require a 12-month minimum contract. Volume discounts are available for 5+ unit orders.

smileyscope.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details3 tiers
1Silver: Entry-level plan for clinics and pathology centres with 4 specialized programs
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Includes: Medical-grade VR hardware, 4 clinical-grade VR programs, virtual training, annual software updates, phone and email support, warranties and replacements. Perfect for high-turnover settings such as vaccinations and phlebotomy.

smileyscope.com
2Gold: Comprehensive plan for hospitals with 50+ programs covering all departments
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Everything in Silver, plus: 50+ clinical-grade VR programs, training customized to your needs, comprehensive warranties and replacements free of charge, bi-annual software updates, priority phone and email support.

smileyscope.com
3Platinum: Enterprise tier with bespoke customization and white-labeling
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Everything in Gold, plus: In-person training customized to your needs, bespoke environment customization and software development, custom marketing collateral development, white-labeling, clinical transformation consulting.

smileyscope.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Lume
Description

Women's health VR product providing evidence-based anxiety and pain reduction for obstetric and gynecological procedures

smileyscope.com
Core offering1 text field

Smileyscope develops and sells a medical-grade virtual reality (VR) digital therapeutics platform that reduces procedural pain and anxiety in healthcare settings. The platform pairs a proprietary antimicrobial, wipeable VR headset with FDA Class II cleared software, including Therapy Mode for pediatric needle procedures (60% pain reduction, 40% anxiety reduction), Imaging Mode for MRI/CT preparation (avoids sedation in up to 92% of cases), and the Lume sub-brand for women's health procedures. The product is sold to hospitals and clinics via tiered subscription plans (Silver, Gold, Platinum) bundling hardware, software, training, warranties, and support under multi-year contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • Up to 60% reduction in procedural pain during pediatric needle procedures
+11 more records
Product overview1 text field

Smileyscope is a digital therapeutics company offering a medical-grade virtual reality platform for healthcare settings. The core product is the Smileyscope VR Platform, which includes specialized modes for different applications: Therapy Mode (FDA-cleared for procedural pain/anxiety), Imaging Mode (for MRI/CT preparation), and Mindfulness and Relaxation. The company also offers a women's health sub-brand called Lume for obstetric and gynecological procedures. The product is delivered through tiered subscription plans (Silver, Gold, Platinum) that bundle medical-grade VR hardware, clinical programs, training, and support services.

Product and service2 records
1Smileyscope VR Platform
CategoryDigital therapeutics platform
Description

Medical-grade virtual reality platform that combines a proprietary antimicrobial, wipeable VR headset with touchscreen interface and FDA Class II cleared software to deliver evidence-based pain and anxiety reduction during medical procedures. Includes Therapy Mode (needle procedures), Imaging Mode (MRI/CT preparation), and a Mindfulness/Relaxation suite, with 50+ clinical-grade programs in 12 audio languages. Sold to hospitals and clinics via tiered subscription plans (Silver, Gold, Platinum) under multi-year contracts.

2Lume
CategoryDigital therapeutics - women's health
Description

Sub-brand of the Smileyscope VR platform purpose-built for women's health applications, providing evidence-based anxiety and pain reduction for obstetric and gynecological procedures including IUD insertion, colposcopy, cervical biopsies, hysteroscopy, pregnancy loss management (MVA), labor and delivery (perineal suturing, epidural), fibroid treatment (Sonata), and sexual health examinations. Clinical evidence shows 89% of women report moderate or significant anxiety reduction and 96% would recommend Lume.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-18
Description

Smileyscope acquired NeuroTrainer to expand its capabilities in human brain performance. This acquisition enhances Smileyscope's evidence-based XR platform by integrating neuroperformance technologies, supporting expansion beyond procedural care into broader brain performance applications.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

King's College Hospital London, Dubai partnered with Smileyscope as a formal design partner guiding new product development across women's health, oncology, dialysis, and interventional radiology. The hospital has adopted Smileyscope as standard care across Emergency, PICU and pediatrics, and serves as a showcase for nurse-led digital innovation in the Middle East. The partnership includes expansion across multiple hospital sites.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Melbourne Dental School is running an MRFF (Medical Research Future Fund)-funded pilot research program evaluating Smileyscope in pediatric dentistry for children aged 3-5. The partnership involves adapting Smileyscope for dental procedures including compatibility with nitrous oxide use, and exploring adult dental applications and health economics research.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Oxford University Hospital NHS Foundation Trust, in partnership with Thinking of Oscar, uses Smileyscope during pediatric IV cannulation to reduce fear, pain and distress. This collaboration supports improved blood draws, IV management, and smoother experiences for patients, families and staff.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Chelsea and Westminster Hospital NHS introduced Lume alongside local anesthetic and oral analgesia for outpatient hysteroscopy. Clinicians report improved patient confidence, reduced reliance on general anesthetic, and calmer, quicker procedures. The hospital serves as a reference site for Lume's women's health applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers16 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Smileyscope

Digital Therapeuticssmileyscope.com

Smileyscope is a medical-grade virtual reality digital therapeutics company that reduces procedural pain and anxiety in pediatric, women's health, and imaging settings. Its FDA Class II-cleared VR platform is deployed across hospitals in North America, Australia, the UK, and the Middle East.

What Smileyscope does

Smileyscope is a Melbourne-founded, Austin-headquartered digital therapeutics company that has developed a medical-grade virtual reality platform to reduce procedural pain and anxiety in clinical settings. Its core technology combines proprietary antimicrobial, wipeable VR hardware (no controllers, touchscreen interface, offline operation without WiFi or Bluetooth) with clinical software built around a patented method called Procedural Choreography™, which reframes real-world sensations into supportive VR experiences synchronized to procedure timing. The platform spans three principal modes — Therapy Mode (FDA Class II cleared as a "Virtual Reality Analgesic"), Imaging Mode (MRI/CT simulation with graded exposure therapy reducing sedation needs by up to 92%), and a Mindfulness/Relaxation suite — and is supported by what the company describes as the largest randomized controlled trial in procedural VR (Chan et al, J Peds, 2019), demonstrating up to 60% pain reduction and 40% anxiety reduction. In 2025 the company extended the platform into women's health with the Lume product and into brain performance via the NeuroTrainer acquisition.

The company generates revenue through tiered multi-year subscription plans (Silver, Gold, Platinum) that bundle VR hardware, software licenses, training, warranties, and support on a 12-month minimum contract basis, with volume discounts for 5+ unit orders. Go-to-market is a hybrid enterprise field sales and inside sales motion targeting children's hospitals, NHS trusts, health systems, and specialty clinics across North America, Australia, the UK, and the Middle East, supplemented by clinical-evidence-led content marketing, conference presence, and reference-customer word of mouth. Customers include St. Jude, Harvard, King's College Hospital Dubai, Monash Children's, Nicklaus Children's, Perth Children's, Oxford University Hospital NHS, Chelsea and Westminster NHS, Rush Medical Center, and others, with adoption reaching 100% of Australian children's hospitals within 12 months of launch in 2022.

The company is operationally profitable in Australia and has raised approximately $10.7M in a 2025 funding round alongside a 2023 seed-prime round led by Breakthrough Victoria, Ten13, Alice Anderson Fund, and MedAngels. With 11-50 employees and FDA Class II, CE, TGA, and MHRA clearances across its primary markets, Smileyscope occupies a regulatory-first position in VR-based procedural analgesia with a defensible clinical evidence base and an expanding footprint across pediatric, women's health, imaging, and brain-performance applications.

Smileyscope firmographics

Firmographics
Name
Smileyscope
Legal name
Smileyscope Holding Inc
Website
https://smileyscope.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Smileyscope is a medical-grade virtual reality digital therapeutics company that reduces procedural pain and anxiety in pediatric, women's health, and imaging settings. Its FDA Class II-cleared VR platform is deployed across hospitals in North America, Australia, the UK, and the Middle East.
Ownership category
akta.pro rank

Smileyscope industry classification

Industry
Product category
Digital Therapeutics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Services-Health Services (8000), Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAL
Pediatrics & Adolescent Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAK
Women’s Health & Fertility Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAFAJAC
Healthcare & Clinical Simulation (Surgery, Nursing, EMT, Patient Interaction)
Education/Education Technology (EdTech) & Digital Learning/AR/VR/XR, Simulations & Immersive Learning

Keywords

  • Virtual reality therapy
  • Pediatric pain management
  • Digital therapeutics
  • Procedural anxiety relief
  • Medical VR hardware

Where Smileyscope is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Smileyscope business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. VR Hardware and Software Subscriptions: The company generates revenue primarily through tiered subscription plans (Silver, Gold, Platinum) that bundle medical-grade VR hardware with software licenses, training, warranties, and ongoing support. Plans require a 12-month minimum contract. Volume discounts are available for 5+ unit orders.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractSilver: Entry-level plan for clinics and pathology centres with 4 specialized programs
SubscriptionMulti-year contractGold: Comprehensive plan for hospitals with 50+ programs covering all departments
SubscriptionMulti-year contractPlatinum: Enterprise tier with bespoke customization and white-labeling

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Smileyscope product offering

Product offering

Core offering

Smileyscope develops and sells a medical-grade virtual reality (VR) digital therapeutics platform that reduces procedural pain and anxiety in healthcare settings. The platform pairs a proprietary antimicrobial, wipeable VR headset with FDA Class II cleared software, including Therapy Mode for pediatric needle procedures (60% pain reduction, 40% anxiety reduction), Imaging Mode for MRI/CT preparation (avoids sedation in up to 92% of cases), and the Lume sub-brand for women's health procedures. The product is sold to hospitals and clinics via tiered subscription plans (Silver, Gold, Platinum) bundling hardware, software, training, warranties, and support under multi-year contracts.

Product overview

Smileyscope is a digital therapeutics company offering a medical-grade virtual reality platform for healthcare settings. The core product is the Smileyscope VR Platform, which includes specialized modes for different applications: Therapy Mode (FDA-cleared for procedural pain/anxiety), Imaging Mode (for MRI/CT preparation), and Mindfulness and Relaxation. The company also offers a women's health sub-brand called Lume for obstetric and gynecological procedures. The product is delivered through tiered subscription plans (Silver, Gold, Platinum) that bundle medical-grade VR hardware, clinical programs, training, and support services.

Differentiator

Problem solved

Functional benefit

Brands

  • Lume: Women's health VR product providing evidence-based anxiety and pain reduction for obstetric and gynecological procedures

Products and services

  • Smileyscope VR Platform Medical-grade virtual reality platform that combines a proprietary antimicrobial, wipeable VR headset with touchscreen interface and FDA Class II cleared software to deliver evidence-based pain and anxiety reduction during medical procedures. Includes Therapy Mode (needle procedures), Imaging Mode (MRI/CT preparation), and a Mindfulness/Relaxation suite, with 50+ clinical-grade programs in 12 audio languages. Sold to hospitals and clinics via tiered subscription plans (Silver, Gold, Platinum) under multi-year contracts.
  • Lume Sub-brand of the Smileyscope VR platform purpose-built for women's health applications, providing evidence-based anxiety and pain reduction for obstetric and gynecological procedures including IUD insertion, colposcopy, cervical biopsies, hysteroscopy, pregnancy loss management (MVA), labor and delivery (perineal suturing, epidural), fibroid treatment (Sonata), and sexual health examinations. Clinical evidence shows 89% of women report moderate or significant anxiety reduction and 96% would recommend Lume.

Quantifiable outcome

  • Up to 60% reduction in procedural pain during pediatric needle procedures
  • +11 more outcomes

Companies that use Smileyscope

Customer profile

Named customers16 records

Segments4 records

Ideal customer profiles4 records

Smileyscope technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Smileyscope partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

  • NeuroTrainercoreStrategic or Co-development Partner · 18 March 2025Smileyscope acquired NeuroTrainer to expand its capabilities in human brain performance. This acquisition enhances Smileyscope's evidence-based XR platform by integrating neuroperformance technologies, supporting expansion beyond procedural care into broader brain performance applications.
  • King's College Hospital London, DubaiflagshipStrategic or Co-development PartnerKing's College Hospital London, Dubai partnered with Smileyscope as a formal design partner guiding new product development across women's health, oncology, dialysis, and interventional radiology. The hospital has adopted Smileyscope as standard care across Emergency, PICU and pediatrics, and serves as a showcase for nurse-led digital innovation in the Middle East. The partnership includes expansion across multiple hospital sites.
  • Melbourne Dental SchoolcoreStrategic or Co-development PartnerMelbourne Dental School is running an MRFF (Medical Research Future Fund)-funded pilot research program evaluating Smileyscope in pediatric dentistry for children aged 3-5. The partnership involves adapting Smileyscope for dental procedures including compatibility with nitrous oxide use, and exploring adult dental applications and health economics research.
  • Oxford University Hospital NHS Foundation Trust / Thinking of OscarminorImplementation/ SI/ Consulting PartnerOxford University Hospital NHS Foundation Trust, in partnership with Thinking of Oscar, uses Smileyscope during pediatric IV cannulation to reduce fear, pain and distress. This collaboration supports improved blood draws, IV management, and smoother experiences for patients, families and staff.
  • Chelsea and Westminster Hospital NHSminorStrategic or Co-development PartnerChelsea and Westminster Hospital NHS introduced Lume alongside local anesthetic and oral analgesia for outpatient hysteroscopy. Clinicians report improved patient confidence, reduced reliance on general anesthetic, and calmer, quicker procedures. The hospital serves as a reference site for Lume's women's health applications.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Smileyscope competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Smileyscope social profiles

Digital presence

Smileyscope compliance and trust

Trust signal

Compliance4 records

Smileyscope financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Smileyscope leadership team

Management profile

Number of profiles

Profiles2 records

Smileyscope subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Smileyscope funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Smileyscope M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Smileyscope

What does Smileyscope do?

Smileyscope develops and sells a medical-grade virtual reality (VR) digital therapeutics platform that reduces procedural pain and anxiety in healthcare settings. The platform pairs a proprietary antimicrobial, wipeable VR headset with FDA Class II cleared software, including Therapy Mode for pediatric needle procedures (60% pain reduction, 40% anxiety reduction), Imaging Mode for MRI/CT preparation (avoids sedation in up to 92% of cases), and the Lume sub-brand for women's health procedures. The product is sold to hospitals and clinics via tiered subscription plans (Silver, Gold, Platinum) bundling hardware, software, training, warranties, and support under multi-year contracts.

Is Smileyscope a public or private company?

Smileyscope is a private company. It is classified as venture growth investor backed and is currently operating.

When was Smileyscope founded?

Smileyscope was founded in 2017. It employs 11 to 50 people.

Where is Smileyscope based?

Smileyscope is headquartered in Melbourne, Australia, in the Oceania region.

How does Smileyscope make money?

One revenue line is on record: VR Hardware and Software Subscriptions.

Does Smileyscope have an API?

No public API is recorded for Smileyscope.

What industry is Smileyscope in?

Smileyscope's product category is Digital Therapeutics. Its primary akta.pro industry code is HLACANAL, Pediatrics & Adolescent Therapeutics (Digital), with a secondary code of HLACANAK, Women’s Health & Fertility Therapeutics (Digital). Its NAICS code is 339112 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireSmileyscope Virtual Reality: Transforming Medical Procedures WorldwideSmileyscope announced landmark achievements, having assisted over 400,000 medical procedures worldwide with adoption by more than 10,000 clinicians, and launched a new website highlighting its clinical community's successes across diverse settings. The company's FDA-cleared VR digital therapeutic platform reduces pain by up to 60% and anxiety by up to 40% during medical procedures, with peer-reviewed clinical studies supporting its use and sedation avoided in over 90% of MRI scans. Originally developed for pediatric procedures, Smileyscope is expanding its reach into women's health while continuing to grow as the world leader in point-of-care VR digital therapeutics.EIN PresswireSmileyscope Expands Evidence-Based XR Platform into Women’s HealthSmileyscope announced the expansion of its evidence-based XR platform into women's health with a new product called 'Lume', backed by clinical milestones and industry recognition. Project Eirene, a program for women undergoing manual-vacuum aspiration after early pregnancy loss at Chelsea & Westminster Hospital, showed strong early results, while a study of 100 women using Smileyscope VR received a Highly Commended award at the 2025 BASHH Annual Conference. The CEO highlighted women's health as a USD 50 billion market opportunity as the company positions itself for the next phase of market evolution.EIN PresswireSmileyscope acquires NeuroTrainer to Expand in Human Brain PerformanceSmileyscope Holding Inc. acquired NeuroTrainer Inc., a neurocognitive optimization tool provider, to expand its brain performance platform. NeuroTrainer CEO Noah Rolland will become Smileyscope's CEO, combining VR pain/anxiety reduction with cognitive training. The move aims to address OECD's estimate of $8.5 trillion in annual lost productivity from impaired brain health.FOX8 WGHPSmileyscope acquires NeuroTrainer to Expand in Human Brain PerformanceSmileyscope Holding Inc. acquired NeuroTrainer Inc., a neurocognitive optimization tool provider, to expand its brain performance platform. NeuroTrainer CEO Noah Rolland will become Smileyscope's CEO, combining VR pain/anxiety reduction with cognitive training. The move aims to address global brain health costs estimated at $8.5 trillion annually.Pulse 2.0Smileyscope: How This Company Uses VR To Help Reduce Patient Pain And AnxietySmileyscope, a digital therapeutics company, uses VR to reduce pain and anxiety during medical procedures. Its underwater VR experience, synchronized with procedures, reduced pain by up to 60% and anxiety by 40% in trials. The company has been used in over 100,000 cases and plans to expand applications.MIT Technology ReviewThe pain is real. The painkillers are virtual reality.Smileyscope, a VR device for children, received FDA clearance to reduce pain during blood draws and IVs. In trials with over 200 children, it cut self-reported pain by up to 60% and anxiety by up to 40%. RelieVRx, another VR therapy, is the first FDA-approved for chronic pain, with 30% of users still seeing pain reduction at three months.Pulse 2.0Smileyscope: Immersive Digital Therapeutics Company Raises Seed RoundSmileyscope, a digital therapeutics company, has closed its seed funding round with investments from Breakthrough Victoria, Ten13, Alice Anderson Fund, and MedAngels. The capital will be used to expand the company's clinical-stage pipeline and grow its presence in health systems across the United States and Australia.FinSMEsSmileyscope Closes Seed Prime RoundSmileyscope, an Austin-based digital therapeutics company, closed a Seed Prime funding round with investments from Breakthrough Victoria, Ten13, Alice Anderson Fund, and MedAngels. The company will utilize the undisclosed capital to expand its clinical-stage pipeline and grow its presence in health systems across the United States and Australia.PrwebSmileyscope Closes Seed Prime Round to Expand Comprehensive Virtual Reality Solutions for HealthcareSmileyscope has closed its Seed Prime funding round, securing investments from Breakthrough Victoria, Ten13, Alice Anderson Fund, and MedAngels. The company intends to use this capital to expand its clinical-stage pipeline and grow its presence in health systems across the United States and Australia.